相关实验视频

Updated: Feb 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

临床特征与肺癌患者的治疗结果相关,这些患者接受了denosumab治疗

B-W Shiau¹, W-H Hsu¹, Y-F Wei²

¹Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.

Clinical oncology (Royal College of Radiologists (Great Britain))

|February 18, 2026

概括

代诺苏马布显著降低了肺癌患者骨转移的死亡率和骨相关事件 (SREs). 这项研究强调了denosumab.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床研究临床研究

背景情况:

肺癌经常转移到骨,导致骨相关事件 (SREs) 和死亡率增加.
单克隆抗体丹诺苏马布 (denosumab) 向RANKL通路,以抑制骨质细胞活性并减少骨再吸收.
德诺苏马布在减少SRE和改善骨转移的各种癌症中的存活率方面的临床益处越来越被认可.

研究的目的:

评估在患有肺癌和骨转移的患者中使用德诺苏马布和2年全因死亡率之间的关联.
评估德诺苏马布对该患者群体骨相关事件 (SREs) 发生率的影响.
提供真实世界的证据,证明德诺苏马布在治疗肺癌骨转移中的有效性.

主要方法:

从TrinetX数据库 (2010-2020) 中使用国际电子健康记录的回顾性队列研究.
包括52521名符合条件的患有肺癌和骨转移的患者,分为德诺苏马布和对照组.
倾向性得分匹配 (PSM) 被应用来平衡基线特征,导致每组有2735名患者用于分析死亡率和SRE.

主要成果:

德诺苏马布的使用与两年内全因死亡率明显降低 (53.8%对55.1%;HR,0.74;P <.001).
接受德诺苏马布的患者经历了更长的中位生存时间 (467 vs 292天) 和更高的生存概率 (P < .001).
在denosumab组 (HR,0.42;P < .001) 观察到发生SRE的风险显著降低,包括骨折和需要放射治疗的骨.

结论:

德诺苏马布治疗与肺癌和骨转移患者的生存率改善和SRE发病率降低有关.
这些发现支持使用denosumab作为管理骨转移的有益治疗选择.
这项研究为现有数据增加了强有力的证据,支持denosumab在瘤实践中的临床实用性.

关键词:

骨转移的发生.这里没有denosumab.肺癌是一种肺癌.死亡率死亡率与骨相关的事件

更多相关视频

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

相关概念视频

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...